Why CervoMed Inc.’s neflamapimod findings may reshape biomarker-driven trials in dementia with Lewy bodies
CervoMed Inc. reveals neflamapimod MRI data in DLB. Discover how biomarker-driven trials could reshape neurodegeneration drug development.
Pharma & Biotech
Pharma & Biotech
Can Genentech’s Enspryng become the first approved treatment for MOGAD after the Phase III METEOROID win?
Genentech’s Enspryng cut MOGAD relapse risk by 68% in Phase III. Read what the data could mean for regulators, clinicians, and the rare disease market.
Pharma & Biotech
Why Lundbeck’s INFUSE study could broaden how migraine treatment success is measured
Lundbeck’s new Vyepti data highlight migraine-related cognitive symptom gains. Read what the INFUSE study could change for clinicians and the CGRP market.
Pharma & Biotech
What Grace Therapeutics’ STRIVE-ON data may change in neurocritical care
Grace Therapeutics’ GTx-104 heads to AAN 2026 just before FDA decision day. Find out what this could change in neurocritical care.
Medical Devices & Diagnostics
FDA clears compact SPRY TMS system: can Soterix Medical disrupt the depression treatment market?
Soterix Medical wins FDA clearance for SPRY TMS in treatment-resistant major depression. What the clearance means for the neuromodulation market. Read the analysis.
Pharma & Biotech
Biohaven ends psychiatric push for BHV-7000 after Phase 2 trial in depression fails to show efficacy
Biohaven Ltd. has reported that BHV-7000, its experimental Kv7 ion channel modulator, failed to meet the primary endpoint in a Phase 2 proof-of-concept trial evaluating the drug in patients with major depressive disorder. The trial assessed changes in depressive symptoms using the Montgomery-Åsberg Depression Rating Scale over six weeks compared to placebo. Although some numerical
Features & Analysis
Is twice-yearly dosing the future of autoimmune care? Inside Amgen’s UPLIZNA playbook for chronic neurology
When Amgen (NASDAQ: AMGN) announced that the U.S. Food and Drug Administration had approved UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis (gMG), the industry’s attention snapped not just to the therapy’s mechanism but to its twice-yearly maintenance schedule. For patients, this marks a seismic shift away from the exhausting cycle of daily oral immunosuppressants